Technology Transfer for Biopharmaceuticals 2012

As biotech products progress from the simple to the complex, so do the demands of the clients for more higher-end, greater value-added activities from their manufacturing counterparts, whether internal or external.

Transfers from lab to pilot plant or from clinical to commercial manufacturing have never been more challenging. Not only are there more regulatory oversight, shorter schedules and higher expectations, the suppliers network is more diverse than ever. Brought on by the major M&As over the recent years, these mega pharmaceutical companies are coming to realize that they need to gain better control of their supply chain in order to minimize risk, enhance productivity, and ensure efficient and smooth technology transfers.